CAU
DNLI icon

Caxton Associates (UK)’s Denali Therapeutics DNLI Stock Holding History

Caxton Associates (UK)’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,229
Closed -$199K – 767
2025
Q2 		$199K Buy
+14,229
New +$200K 0.01% 632

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Caxton Associates (UK)'s DNLI Position: Q3 2025 in Review

Caxton Associates (UK) sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 14,229 shares — an estimated $199K sold.

Caxton Associates (UK) first reported a position in DNLI in Q2 2025 and held it in 1 quarter. The position peaked at $199K in Q2 2025. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Caxton Associates (UK) reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 14,229 Denali Therapeutics shares in Q3 2025, an estimated $199K.
  • Caxton Associates (UK) first reported a position in Denali Therapeutics in Q2 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s Denali Therapeutics position peaked at $199K in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Caxton Associates (UK)'s 13F filing for Q3 2025, filed 17 Nov 2025.